CIDP and Home Infusion: IVIG Treatment, Dosing Schedule, and Long-Term Management

July 16, 2026

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated neurological disorder in which the body's immune system attacks the myelin sheath surrounding peripheral nerves, causing progressive weakness, numbness, and functional impairment. CIDP is rare, affecting approximately 1 to 9 per 100,000 people, but it is one of the most common treatable immune-mediated neuropathies, and intravenous immunoglobulin (IVIG) is one of its most effective and widely used treatments.


For many CIDP patients on stable maintenance IVIG therapy, home infusion is the most convenient and clinically appropriate setting for ongoing treatment. Pharmko supports CIDP patients and their neurologists across 22+ states with the clinical coordination and nursing support that makes home IVIG reliable for this specific patient population.


How IVIG Works for CIDP


The exact mechanism by which IVIG benefits CIDP patients is not fully understood, but several pathways have been identified. IVIG appears to modulate the immune system by:


  • Neutralizing pathological antibodies that target myelin-associated glycoprotein and other peripheral nerve components
  • Blocking Fc receptors on macrophages and other immune cells, reducing their ability to damage nerve tissue
  • Providing anti-idiotypic antibodies that regulate autoreactive B cells
  • Modulating complement activation and cytokine signaling involved in nerve inflammation


The clinical result is stabilization or improvement of neurological function, reduced weakness, improved sensation, and better functional capacity, that is maintained as long as IVIG is continued on schedule.


Diagnosis: How CIDP Is Confirmed


CIDP diagnosis can be challenging because its presentation overlaps with other neuropathies. The European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) criteria are the most widely used diagnostic framework and require:


  • Progressive or relapsing weakness and sensory dysfunction in more than one limb for at least 8 weeks
  • Electrodiagnostic (nerve conduction study) evidence of demyelination in at least two nerves
  • In atypical presentations: supporting evidence from CSF analysis, nerve biopsy, or MRI


CIDP variants, including multifocal acquired demyelinating sensory and motor neuropathy (MADSAM), pure motor CIDP, and sensory CIDP, may present differently and may respond differently to IVIG compared to typical CIDP.


IVIG Dosing Schedule for CIDP


Induction phase


Treatment typically begins with a loading course of IVIG to establish therapeutic IgG levels and achieve initial clinical response. Standard induction dosing is 2 g/kg total, divided over 2 to 5 consecutive days. Some neurologists use a 1 g/kg single-day loading dose as an alternative in patients who tolerate rapid infusions well.


Most patients begin to notice improvement within 2 to 6 weeks of the loading course. If there is no meaningful response after a full induction course, the diagnosis of CIDP should be reconsidered.


Maintenance phase


Patients who respond to induction therapy require ongoing maintenance IVIG to prevent relapse. Standard maintenance dosing is 1 g/kg every 3 weeks, or 0.5 g/kg every 2 weeks, though the optimal schedule is individualized based on clinical response, symptom trajectory between doses, and patient lifestyle.


Some patients require more frequent dosing to maintain function throughout the dosing interval (a phenomenon called 'wearing off' before the next dose is due). Others achieve durable remission and can extend intervals or attempt tapering after a period of sustained stability, always under neurologist guidance.


Transitioning from Infusion Center to Home IVIG


Most CIDP patients begin IVIG at an infusion center or hospital outpatient department during the induction phase, where reactions can be monitored and dosing adjusted. Once:


  • The maintenance dose and schedule are established
  • The patient has tolerated infusions without significant reactions across multiple doses
  • The neurologist has assessed the patient as appropriate for home-based administration


...home IVIG becomes a natural and practical transition. Our guide on IVIG therapy at home covers the home setup process, what nursing visits include, and how supply delivery is coordinated. For patients newly diagnosed with an immune-mediated condition and just beginning to research IVIG, our broader guide on primary immune deficiency and IVIG provides useful foundational context.


What to Expect from Long-Term CIDP Management


CIDP is typically a long-term condition. Some patients achieve remission and can eventually discontinue IVIG; many require indefinite maintenance therapy. Long-term management considerations include:


  • Regular neurological assessment, strength testing, functional scales, and nerve conduction studies at defined intervals to confirm continued response and detect relapse early
  • IgG trough monitoring, measuring IgG levels before each maintenance dose to confirm therapeutic levels are being maintained
  • Dose adjustment over time, weight changes, clinical status changes, or evolving response patterns may require formula or schedule modifications
  • Alternative therapies, subcutaneous immunoglobulin (SCIG) is an option for some CIDP patients who prefer self-administered weekly dosing over monthly IV infusions


Know which symptoms should prompt an immediate call between IVIG doses, worsening weakness, new falls, or significant functional decline before the next scheduled infusion may indicate the need for a supplemental dose or schedule change. Our after-hours support line is available for urgent concerns.


Insurance Coverage for CIDP IVIG


IVIG for CIDP is covered by Medicare Part B and most commercial insurance plans when the diagnosis is confirmed by nerve conduction studies and the patient meets clinical response criteria. Prior authorization is required and must include diagnostic criteria, evidence of functional impairment, and documentation of clinical response to prior IVIG therapy. Pharmko manages the full authorization process and coordinates with your neurologist's office to compile the supporting documentation.


→ Contact Pharmko to start CIDP IVIG therapy: 1-877-540-2003


Person living with end stage renal disease going about an ordinary morning at home
September 1, 2026
Straight answers to what people on dialysis ask most: nutrition, phosphate, energy, travel, and the emotional weight of ongoing treatment.
Handwritten list of questions prepared for a dialysis appointment about IDPN therapy
September 1, 2026
The questions worth bringing to your nephrologist or dietitian before starting intradialytic parenteral nutrition, grouped and ready to print.
Adult daughter and her mother reviewing a delivery schedule together in the kitchen at home
September 1, 2026
A practical guide for caregivers: what your role is, what the pharmacy can share with you, what to keep track of, and how to protect your own energy.
Family sharing a meal at home while one member on parenteral nutrition joins the table
September 1, 2026
Whether you can eat on parenteral nutrition, why appetite and taste change, and how to handle meals with family while receiving IV nutrition.
Suitcase packed with a small cooler and paperwork for traveling while on parenteral nutrition
August 31, 2026
How to plan a trip on TPN or home parenteral nutrition: supplies, refrigeration, air travel documentation, and how far ahead to call your pharmacy.
Home delivery of TPN supplies unpacked on a kitchen table during the first week of therapy
August 31, 2026
A day-by-day look at starting total parenteral nutrition at home: the first delivery, the first infusion, night one, and when to call for help.
Dialysis center staff coordinating phosphate binder supply with a pharmacy partner
August 11, 2026
What dialysis centers should look for in a phosphate binder supply partner: reliable delivery, formulary breadth, insurance support, and coordination.
Renal dietitian reviewing phosphate levels with a dialysis patient
August 11, 2026
How hyperphosphatemia is managed in ESRD dialysis patients, diet, dialysis, and phosphate binders, and why reliable binder supply keeps therapy on track.
July 29, 2026
Compounded medications are a routine part of modern care, but unlike mass-manufactured drugs, each one is prepared individually, which means the standards behind its preparation carry real weight. For providers who order or refer for compounded therapies, a working understanding of those standards is the clearest way to judge whether a pharmacy is safe to trust. This overview covers the standards that govern sterile compounding and what they mean for the medications your patients receive. Why Standards Matter More in Compounding A commercially manufactured drug is produced under FDA oversight in large, validated batches. A compounded medication is prepared for an individual patient, often in small quantities, sometimes because no commercial equivalent exists. That flexibility is exactly why it's clinically valuable — and why the standards around preparation exist. Without rigorous controls, the same customization that helps patients could introduce contamination or error. Our guide to our sterile compounding pharmacy describes how those controls come together in practice. The Regulatory Landscape Sterile compounding sits within a layered framework: The United States Pharmacopeia (USP) publishes the general chapters, most importantly <797> and <800>, that define how compounded preparations should be made and handled. State boards of pharmacy license and inspect pharmacies, including where they're permitted to ship. Multi-state operations must maintain licensure in each state they serve. Accreditation bodies (ACHC, NABP, PCAB) provide independent verification that a pharmacy meets recognized standards. Together, these create the accountability structure behind every compounded dose. USP <797>: Sterile Preparations USP <797> is the cornerstone standard for compounded sterile preparations. It governs the conditions and practices required to keep a preparation free of contamination, including personnel training and garbing, ISO-classified air quality and engineering controls, environmental monitoring, and beyond-use dating. For any medication infused directly into the body, <797> compliance is the baseline expectation, not a premium feature. USP <800>: Hazardous Drugs USP <800> adds a containment layer for hazardous drugs, protecting personnel, patients, and the environment from unintended exposure. It specifies containment engineering controls, PPE, and validated handling procedures for drugs identified as hazardous. When a preparation is both sterile and hazardous, it must satisfy <797> and <800> together. For the details, see our breakdown of USP <800> requirements . Accreditation: Independent Verification Standards are only meaningful if someone checks that they're being met. Accreditation from ACHC, NABP, and PCAB means a pharmacy has been inspected against national benchmarks by an outside authority. For a provider, accreditation is a shortcut to confidence: it signals that the pharmacy's claims about its processes have been independently validated. The Quality-Control Process Behind the standards is a repeatable process that governs each preparation: Pharmacist review of the prescription for appropriateness, compatibility, and dosing Preparation by trained technicians under aseptic conditions In-process and final verification by a licensed pharmacist Sterility testing or filtration validation where required This chain is what turns a standard on paper into a safe medication in a patient's hands. What This Means When You Order When you refer a patient for a compounded therapy, you're effectively extending your own standard of care into another facility. Knowing that a pharmacy is USP-compliant, accredited, and pharmacist-led lets you refer with confidence that the medication will meet the same expectations you'd hold for anything you administer yourself. If you're weighing options, our guide on how to choose a compounding partner walks through the criteria. The Pharmko Standard Pharmko compounds every TPN, IDPN, and IPN preparation in a USP <797>-compliant, ISO Class 5 cleanroom, under ACHC, NABP, and PCAB accreditation, with a licensed pharmacist reviewing and releasing each formula. For the patients who receive our preparations, many of them managing End Stage Renal Disease (ESRD), that standard is the point. Refer a Patient → · [1 (877) 540-2003]
Physician evaluating a sterile compounding pharmacy partner
July 29, 2026
How to evaluate a sterile compounding pharmacy: accreditation, USP compliance, clinical support, turnaround, and the questions every practice should ask.
Show More